These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19878649)

  • 41. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.
    Persson L; Gälman C; Angelin B; Rudling M
    Endocrinology; 2009 Mar; 150(3):1140-6. PubMed ID: 19008317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
    Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
    Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
    BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.
    Mbikay M; Mayne J; Chrétien M
    J Diabetes; 2013 Dec; 5(4):391-405. PubMed ID: 23714205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intracellular and extracellular regulatory circuits.
    Saitoski K; Ryaboshapkina M; Hamza GM; Jarnuczak AF; Berthault C; Carlotti F; Armanet M; Sengupta K; Underwood CR; Andersson S; Guillas I; Le Goff W; Scharfmann R
    J Biol Chem; 2022 Jul; 298(7):102096. PubMed ID: 35660019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.
    Miao J; Manthena PV; Haas ME; Ling AV; Shin DJ; Graham MJ; Crooke RM; Liu J; Biddinger SB
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1589-96. PubMed ID: 26023080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Self-association of human PCSK9 correlates with its LDLR-degrading activity.
    Fan D; Yancey PG; Qiu S; Ding L; Weeber EJ; Linton MF; Fazio S
    Biochemistry; 2008 Feb; 47(6):1631-9. PubMed ID: 18197702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
    Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
    J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation.
    Poirier S; Mamarbachi M; Chen WT; Lee AS; Mayer G
    Cell Rep; 2015 Dec; 13(10):2064-71. PubMed ID: 26628375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
    Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
    J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation.
    Chen Y; Wang H; Yu L; Yu X; Qian YW; Cao G; Wang J
    Biochem Biophys Res Commun; 2011 Nov; 415(3):515-8. PubMed ID: 22074827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inflammation stimulates the expression of PCSK9.
    Feingold KR; Moser AH; Shigenaga JK; Patzek SM; Grunfeld C
    Biochem Biophys Res Commun; 2008 Sep; 374(2):341-4. PubMed ID: 18638454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Liver Clock Controls Cholesterol Homeostasis through Trib1 Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR) Axis.
    Ma D; Liu T; Chang L; Rui C; Xiao Y; Li S; Hogenesch JB; Chen YE; Lin JD
    J Biol Chem; 2015 Dec; 290(52):31003-12. PubMed ID: 26547624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
    Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
    Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PCSK9 and carbohydrate metabolism: A double-edged sword.
    Filippatos TD; Filippas-Ntekouan S; Pappa E; Panagiotopoulou T; Tsimihodimos V; Elisaf MS
    World J Diabetes; 2017 Jul; 8(7):311-316. PubMed ID: 28751953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholesterol reduction ameliorates glucose-induced calcium handling and insulin secretion in islets from low-density lipoprotein receptor knockout mice.
    Souza JC; Vanzela EC; Ribeiro RA; Rezende LF; de Oliveira CA; Carneiro EM; Oliveira HC; Boschero AC
    Biochim Biophys Acta; 2013 Apr; 1831(4):769-75. PubMed ID: 23298460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.